Related Experiment Video
Updated: Apr 17, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
RhoGTPases - A novel link between cytoskeleton organization and cisplatin resistance
1Princess Margaret Cancer Center, University Health Network, Toronto Medical Discovery Tower, 101 College Street, Toronto, Ontario, Canada M5G 1L7.
Abstract:
For more than three decades, platinum compounds have been the first line treatment for a wide spectrum of solid tumors. Yet, cisplatin resistance is a major impediment in cancer therapy, and deciphering the mechanisms underlying chemoresistance is crucial for the development of novel therapies with enhanced efficacy. The Rho subfamily of small GTPases plays a significant role in cancer progression, and a growing body of evidence points toward the involvement of these proteins in anticancer drug resistance, including cisplatin resistance. The cycling between active and inactive states, governed by the balance between their GEFs, GAPs and GDIs, RhoGTPases, acts as molecular switches with a pivotal role in actin cytoskeleton organization. The Rho subfamily of proteins is involved in many key cellular processes including adhesion, vesicular trafficking, proliferation, survival, cell morphology and cell-matrix interactions. Although RhoA, RhoB and RhoC are highly homologous and share some upstream regulators and downstream effectors, they each have different roles in cancer progression and chemoresistance. While RhoA and RhoC are upregulated in many tumors and can stimulate transformation, RhoB appears to exhibit tumor suppressor characteristics with proapoptotic effects. In the current review, we discuss the role of Rho subfamily of proteins in cancer, and focus on their involvement in intrinsic and acquired drug resistance.
Insights
Platinum compounds are vital cancer treatments, but cisplatin resistance hinders efficacy. Understanding Rho GTPases
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Platinum compounds, including cisplatin, are primary treatments for numerous solid tumors.
- Cisplatin resistance significantly impedes effective cancer therapy.
- Rho GTPases are critical regulators of cellular processes and implicated in cancer progression.
Purpose of the Study:
- To review the role of the Rho subfamily of small GTPases in cancer.
- To focus on the involvement of Rho GTPases in intrinsic and acquired cisplatin resistance.
Main Methods:
- Literature review of studies investigating Rho GTPases in cancer and drug resistance.
- Analysis of the regulatory mechanisms (GEFs, GAPs, GDIs) controlling Rho GTPase activity.
- Examination of the distinct roles of RhoA, RhoB, and RhoC in cancer progression and chemoresistance.
Main Results:
- Rho GTPases are molecular switches crucial for actin cytoskeleton organization and cellular functions like adhesion, trafficking, proliferation, and survival.
- RhoA and RhoC are frequently upregulated in tumors, promoting transformation.
- RhoB exhibits tumor suppressor characteristics, mediating proapoptotic effects.
Conclusions:
- The Rho subfamily of proteins plays a multifaceted role in cancer development and progression.
- Understanding the specific contributions of RhoA, RhoB, and RhoC to chemoresistance is essential for developing novel therapeutic strategies.
- Targeting Rho GTPase pathways may offer new avenues to overcome cisplatin resistance in cancer treatment.
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
GTPases and their Regulation
Large G-proteins,...
GTPases and their Regulation
Activation and Inactivation of G Proteins
Cell Polarization by Rho Proteins
The Ras Gene
Ras is a...

